A Canadian team has found that compounds
from sea sponges could be useful for treating cystic fibrosis. The compounds
work in part by inhibiting a new family of targets for the disease: poly(ADP-ribose) polymerases.1 The researchers now plan to work backward
to uncover why blocking these polymerases improves the function of cystic fibrosis transmembrane
conductance regulator, the mutated protein
that causes cystic fibrosis.
Carlile and Thomas screened a library of 720 compounds from
marine organisms and found that latonduine A and latonduine B (ethyl) increased
the surface expression of transgenic DF508 CFTR
in hamster cells compared with vehicle.
for the course
The question now is why reducing PARP activity has a
beneficial effect on DF508 CFTR.
Osherovich, L. SciBX 5(46); doi:10.1038/scibx.2012.1200
Published online Nov. 29, 2012
1. Carlile, G.W. et al.
Chem. Biol.; published online Oct. 26, 2012;
Contact: Graeme W. Carlile, McGill University, Montreal, Quebec, Canada
2. Jwa, M. & Chang, P.
Nat. Cell Biol. 14, 1223-1230 (2012)
3. Van Goor, F. et al.
Proc. Natl. Acad. Sci. USA 108, 18843-18848 (2011)
COMPANIES AND INSTITUTIONS MENTIONED
Abbott Laboratories (NYSE:ABT), Abbott Park, Ill.
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Cancer Research UK, London, U.K.
Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo.
Cystic Fibrosis Foundation, Bethesda, Md.
Cystic Fibrosis Foundation Therapeutics Inc., Bethesda, Md.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Massachusetts Institute of Technology, Cambridge, Mass.
McGill University, Montreal, Quebec, Canada
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Proteostasis Therapeutics Inc., Cambridge, Mass.
The University of British Columbia, Vancouver, British Columbia, Canada
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass.